Acta cardiologica最新文献_第3页

Office white-coat effect tail and long-term cardiovascular risks in 60-year follow-up of the European cohorts of the Seven Countries Study. 办公室白大褂效应尾和七国研究欧洲队列60年随访的长期心血管风险

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI: 10.1080/00015385.2025.2467006

Xavier Humbert, Andry Rabiaza, Anthony Kafatos, Paolo Piras, Hanna Tolonen, Paolo-Emilio Puddu

{"title":"Office white-coat effect tail and long-term cardiovascular risks in 60-year follow-up of the European cohorts of the Seven Countries Study.","authors":"Xavier Humbert, Andry Rabiaza, Anthony Kafatos, Paolo Piras, Hanna Tolonen, Paolo-Emilio Puddu","doi":"10.1080/00015385.2025.2467006","DOIUrl":"10.1080/00015385.2025.2467006","url":null,"abstract":"Aim: The aim of this study was to determine whether the office white-coat effect tail (OWCET), defined as decreasing of SBP ≥10 mmHg in multiple office systolic blood pressure measures, predicts major long-term fatal events in the nearly extinct European cohorts of the Seven Country Study (ECSCS).Material and methods: In the present analysis, 4,937 men (49 ± 5 years) were included. All-cause mortality and specific mortalities [cardiovascular mortality (CVD) including stroke, coronary heart disease (CHD) death as well as heart disease of uncertain aetiology (HDUE)] were considered using Cox models. Also non-CVD deaths were studied by Fine-Gray competing risk analysis.Results: At inclusion, subjects with OWCET were significantly more hypertensive. After 60-year follow-up, OWCET was not associated with risk of both CVD [aHR: 0.95 (95% CI: 0.82-1.03), p = 0.5] and all-cause death [aHR: 0.92 (95% CI: 0.82-1.03), p = 0.16] independently of traditional risk factors (age, SBP, BMI, total cholesterol and cigarettes) in ECSCS. Same results were found for Northern and Southern Europe cohorts of ECSCS concerning CVD death [aHR: 0.98 (95% CI: 0.76-1.26), p = 0.85 and aHR: 0.95 (95% CI: 0.74-1.20), p = 0.66] and all-cause death, respectively [aHR: 0.90 (95% CI: 0.75-1.07), p = 0.23 and aHR: 0.93 (95% CI: 0.79-1.09), p = 0.38].Conclusions: In a general population of men, OWCET is not associated to CVD or non-CVD and all-cause mortality and consequently cannot improve stratification of long-term CVD risks in ECSCS.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"173-180"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myocardial work in ischaemic heart disease. 缺血性心脏病的心肌作用。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI: 10.1080/00015385.2025.2457179

María Elena Sánchez, Mercedes Panno, Mateo Giordano, Anabel Gafni

引用次数: 0

Cardiac 'quartet': a rare case of quadricuspid aortic valve combined with ascending aortic aneurysm. 心脏“四重奏”：罕见的四尖瓣主动脉瓣合并升主动脉瘤1例。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-31 DOI: 10.1080/00015385.2025.2484859

Mengqi Tang, Juan Xia, Yafeng He, Yanling Xue, Zifan Wu, Xiaojing Ma

引用次数: 0

Complete heart block after occlusion and repair for perimembranous ventricular septal defect. 膜周围室间隔缺损的完全性心脏传导阻滞和修复。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-31 DOI: 10.1080/00015385.2025.2480961

Li Lin, Wanhua Chen, Hang Chen, Jianwen Liu, Kanghui Chen, Lianglong Chen, Liangwan Chen, Zhaoyang Chen

{"title":"Complete heart block after occlusion and repair for perimembranous ventricular septal defect.","authors":"Li Lin, Wanhua Chen, Hang Chen, Jianwen Liu, Kanghui Chen, Lianglong Chen, Liangwan Chen, Zhaoyang Chen","doi":"10.1080/00015385.2025.2480961","DOIUrl":"https://doi.org/10.1080/00015385.2025.2480961","url":null,"abstract":"Background: Complete atrioventricular conduction block (CAVB) is a major complication of the repair and occlusion of perimembranous ventricular septal defects (pmVSDs).Objective: This study aimed to analyse the incidence and risk factors of CAVB after occlusion and repair of pmVSD.Methods: We reviewed patients with pmVSDs who underwent occlusion and repair between January 2010 and January 2022. Permanent CAVB was defined as a CAVB requiring permanent pacemaker implantation or occluder extraction.Results: Of 2436 patients who underwent pmVSD repair, 7 (0.3%) developed permanent CAVB. In all, 16 (0.7%) of the 2200 patients in the device group developed permanent CAVBs. All permanent CAVBs in the repair group occurred during hospital stay. In contrast, eight (50%) permanent CAVBs in the device group occurred over 1 month. A large pmVSD size (odds ratio [OR], 1.575; 95% confidence interval [CI], 1.260-1.970, p < 0.001) and device/defect ratio (OR, 2.608; 95% CI, 1.587-4.287, p < 0.001) were independent risk factors for permanent CAVB after surgical repair and device occlusion, respectively. Multivariate regression showed that device occlusion versus surgical repair was associated with a significantly higher risk of permanent CAVBs (OR, 4.675; 95% CI, 1.586-13.780, p = 0.005).Conclusion: The incidence rates of permanent CAVB after device occlusion and surgical repair were 0.7% and 0.3%, respectively. Large VSD size and device/defect ratio were independently associated with permanent CAVB after surgical repair and device occlusion, respectively. Compared with surgical repair, device occlusion was associated with a significantly higher risk of permanent CAVB after pmVSD closure.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vericiguat versus sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction in China: a cost-utility analysis. Vericiguat与sacubitril/缬沙坦在中国治疗心力衰竭并降低射血分数：成本效用分析

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-31 DOI: 10.1080/00015385.2025.2484848

Xingyuan Zhao, Nan Hu, Liying Wang, Zongling Xia

{"title":"Vericiguat versus sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction in China: a cost-utility analysis.","authors":"Xingyuan Zhao, Nan Hu, Liying Wang, Zongling Xia","doi":"10.1080/00015385.2025.2484848","DOIUrl":"https://doi.org/10.1080/00015385.2025.2484848","url":null,"abstract":"Background: PARADIGM-HF and VICTORIA studies have shown that treatment with sacubitril/valsartan or vericiguat could reduce cardiovascular mortality and hospitalisation in the patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, the cost-utility analysis of adding sacubitril/valsartan or vericiguat to the standard treatment of heart failure in Chinese patients with HFrEF was still unclear.Methods: Based on the Chinese healthcare system, a multi-state Markov model has been established for the cost-utility analysis and compared with the results of VICTORIA study subgroups and relevant local data in China. This model simulated the direct medical costs and quality-adjusted life years (QALYs) of HFrEF patients over a period of 20 years, in which these patients were treated with the standard treatment of heart failure and either adding sacubitril/valsartan or vericiguat. Moreover, incremental cost-utility ratio (ICUR) and incremental net monetary benefit (INMB) were also analysed and the robustness of the results was verified by using sensitivity analysis.Results: In the base case study, according to the Chinese HFrEF patients, the total costs for the sacubitril/valsartan group and the vericiguat group were 4,237.42 USD and 4,618.59 USD, respectively, and the total utility was 3.62 and 3.48 QALYs, respectively. The ICUR was -2,611.68 USD/QALY, and the INMB was -5,772.32 USD. The sensitivity analysis indicated that the results were robust. The results of scenario analysis and base-case analysis were basically consistent.Conclusions: On the standard treatment of heart failure, adding sacubitril/valsartan alone was more cost-effective than adding vericiguat alone for the treatment of HFrEF.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unusual late presentation of symptomatic type II popliteal artery entrapment syndrome in a 62 years adult. 62岁成人不寻常的晚期症状型腘动脉卡压综合征。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-29 DOI: 10.1080/00015385.2025.2484861

Gourav Saini, Resham Singh, Renu Yadav, Priyanka Singh

引用次数: 0

Platelet-to-lymphocyte ratio (PLR) for coronary artery lesions in Kawasaki disease: correspondence. 川崎病冠状动脉病变的血小板与淋巴细胞比值：对应关系。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-27 DOI: 10.1080/00015385.2025.2484837

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Association of the 'Life's Essential 8' with FeNO and all-cause mortality: a population-based study in U.S. adults. “生命必需的8项”与FeNO和全因死亡率的关系：一项基于美国成年人的人群研究。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-24 DOI: 10.1080/00015385.2025.2480960

Kai Li, Jie Feng, Leilei Han, Yanqing Wu

{"title":"Association of the 'Life's Essential 8' with FeNO and all-cause mortality: a population-based study in U.S. adults.","authors":"Kai Li, Jie Feng, Leilei Han, Yanqing Wu","doi":"10.1080/00015385.2025.2480960","DOIUrl":"https://doi.org/10.1080/00015385.2025.2480960","url":null,"abstract":"Background: The 'Life's Essential 8' (LE8), a recent framework introduced by the American Heart Association (AHA), refines and expands the concept of wellness, with a particular emphasis on promoting cardiovascular health. The fractional exhaled nitric oxide (FeNO) score, a non-invasive and easily obtainable biomarker, offers a convenient method for evaluating respiratory conditions such as asthma. While both LE8 and FeNO represent emerging and widely recognised indicators of health, research exploring their interrelationship remains limited. This study aims to examine the associations between LE8, FeNO, and all-cause mortality.Methods: A total of 14,293 eligible participants, aged ≥18 years, were enrolled from the National Health and Nutrition Examination Survey (NHANES) database spanning 2007-2012. This observational cohort study integrated baseline NHANES data with mortality records from the U.S. National Death Index through 2021. To assess the association between LE8 and FeNO, we employed multiple linear regression models, both with and without adjustments for demographic factors and health-related practices. Additionally, these data were utilised to explore the relationships between various health determinants and all-cause mortality.Results: In this observational analysis, we found that an increase in the LE8 score was positively associated with elevated FeNO levels, a marker implicated in immune responses to respiratory diseases. Furthermore, higher LE8 scores were inversely associated with survival risk in the population, suggesting a potential protective effect on survival in the studied population.Conclusions: Our findings suggest that primary and tertiary prevention efforts to promote cardiovascular health should be strengthened, especially those targeting unhealthy factors and behaviours to improve cardiorespiratory fitness and reduce survival risk.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediction of cardiovascular disease using blood pressure indices: more than just the level? 利用血压指标预测心血管疾病：不仅仅是水平？

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-24 DOI: 10.1080/00015385.2025.2480940

Guy De Backer

引用次数: 0

Cardiac angiosarcoma. Cardiac血管肉瘤。

IF 2.1 4区医学

Acta cardiologica Pub Date : 2025-03-21 DOI: 10.1080/00015385.2025.2480989

A Maiorana, P Lancellotti

引用次数: 0